Charbel Chidiac

Dr. Charbel Chidiac

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2024 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
CCCharbel Chidiac
Charbel Chidiac
OIOussama Issa
Oussama Issa
AGAlejandro V. Garcia
Alejandro V. Garcia
DRDaniel S. Rhee
Daniel S. Rhee
MSMark B. Slidell
Mark B. Slidell

6 May 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
CCCharbel Chidiac
Charbel Chidiac
PMPallavi Menon
Pallavi Menon
MSMark B. Slidell
Mark B. Slidell
SKShaun M. Kunisaki
Shaun M. Kunisaki
AGAlejandro V. Garcia
Alejandro V. Garcia
DRDaniel S. Rhee
Daniel S. Rhee

15 February 2024 in Journal of Surgical Research
Verified
Journal Article
Closed access
CCCharbel Chidiac
Charbel Chidiac
KWKristin Wharton
Kristin Wharton
AGAlejandro V. Garcia
Alejandro V. Garcia
DRDaniel S. Rhee
Daniel S. Rhee

23 June 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
ASAnne M. Sescleifer
Anne M. Sescleifer
CCCharbel Chidiac
Charbel Chidiac
ZHZane J. Hellmann
Zane J. Hellmann
KMKatherine M. McDermott
Katherine M. McDermott
AGAlejandro V. Garcia
Alejandro V. Garcia
SKShaun Michael Kunisaki
Shaun Michael Kunisaki

27 June 2023 in Surgery in Practice and Science
Verified
Journal Article
Open access
CCCharbel Chidiac
Charbel Chidiac
AHAndrew Hu
Andrew Hu
EDEmily Dunn
Emily Dunn
DRDaniel S. Rhee
Daniel S. Rhee
The presence of image‑defined risk factors (IDRF) in neuroblastoma plays a large role in decision making for primary resection versus neoadjuvant chemotherapy. This study investigates how the number and type of IDRFs affect surgical outcomes for primary resection of neuroblastoma. A retrospective review was performed including patients diagnosed with neuroblastoma with at least one IDRF who underwent primary resection of their tumor between 2003 and 2017. Cross sectional imaging was reviewed by a single pediatric radiologist for determination of IDRFs. Surgical outcomes were compared by <5 versus ≥5 IDRFs and vascular or non‑vascular involvement. A total of 28 patients were included in the study, 18 with <5 IDRFs and 10 with ≥5 IDRFs. Fifteen patients had vascular involvement and 13 did not. Nine were adrenal, 6 were cervicothoracic, and 5 were abdominal non-adrenal. Patients with ≥5 IDRFs were found to have an increased rate of complications (40% vs 0%; p<0.01), operative time (318 vs 148 min; p<0.01), estimated blood loss (187 mL vs 45 mL; p<0.01), length of stay (9.6 vs 4.9 days; p<0.01), and hospital readmission (20% vs 0%; p = 0.04). No differences were found in degree of resection (p = 0.06). All complications occurred with vascular involvement IDRFs compared to non‑vascular IDRFs (27% vs 0%; p = 0.04). The presence of ≥5 IDRFs and vascular involvement increases complications associated with primary resection of neuroblastoma. Our findings underscore the importance of neoadjuvant chemotherapy prior to resection. Further studies are required to determine how different IDRFs influence surgical risk.

24 July 2024 in Journal of Surgical Research
Verified
Journal Article
Closed access
KWKristin Wharton
Kristin Wharton
CCCharbel Chidiac
Charbel Chidiac
CLCarla Lopez
Carla Lopez
JHJoann Hunsberger
Joann Hunsberger
DRDaniel Rhee
Daniel Rhee
AGAlejandro V. Garcia
Alejandro V. Garcia